Dr. Yao Zhu talks to Dr. Nguyen: Advances in Radiotherapy and Surgical Treatment of Prostate Cancer at ASCO-GU 2023

Dr. Yao Zhu talks to Dr. Nguyen: Advances in Radiotherapy and Surgical Treatment of Prostate Cancer at ASCO-GU 2023

The 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU 2023) has concluded. During this conference, several studies related to early-stage/ localized prostate cancer radiotherapy or surgical treatment were presented as oral reports. Among them, the FORMULA-509 study presented by Dr. Paul L. Nguyen of the Dana-Farber Cancer Institute at Harvard Medical School showed that for high-risk patients with biochemical recurrence after radical surgery, combining 6 months of ADT (Androgen Deprivation Therapy) with novel hormonal therapy on top of salvage radiotherapy can improve patient survival. "Oncology Frontier" invited Dr. Zhu Yao from Fudan University Shanghai Cancer Center to have a discussion with Dr. Nguyen, delving into the interpretation of the FORMULA-509 study and other prostate cancer surgery and radiotherapy-related research presented at the conference.
Dr. Ming Zhao: Key Clinical Research in Hepatocellular Carcinoma|Highlights from APPLE 2023

Dr. Ming Zhao: Key Clinical Research in Hepatocellular Carcinoma|Highlights from APPLE 2023

From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) was held in Seoul, South Korea. Hepatocellular carcinoma (HCC) experts from around the world gathered to rekindle academic discussions on HCC's basics, clinical aspects, research, and technology offline. The conference featured the latest research results from over a thousand scholars representing more than 50 countries. In this publication, Dr. Ming Zhao from Sun Yat-sen University Cancer Center, China, offers insightful interpretations of the significant clinical research emerging from APPLE 2023 for the benefit of our readers.
Interview with Minggui Wang at ECCMID 2023

Interview with Minggui Wang at ECCMID 2023

The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) recently took place in Copenhagen, Denmark, drawing attention as one of the first major in-person events since the easing of the COVID-19 pandemic. The event, a hallmark in the world of infectious diseases and clinical microbiology, attracted numerous participants, among whom was Dr. Minggui Wang, the director of the Institute of Antibiotics, Huashan Hospital, Fudan University. Dr. Wang shared insights on the advances and experiences at the conference, with a particular focus on fungal infections.
Dr. Michelle Seif: CAR-T Therapy’s Potential in Treating Fungal Infections丨ECCMID 2023

Dr. Michelle Seif: CAR-T Therapy’s Potential in Treating Fungal Infections丨ECCMID 2023

At the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023), the prospect of utilizing Chimeric Antigen Receptor T-cells (CAR-T) for medical treatments has emerged as a promising avenue, especially in the realm of infectious diseases. Notably, Dr. Michelle Seif from the University Hospital Würzburg, Germany, has presented new findings that expand upon the potential use of CAR-T therapy in fungal infections.
Dr. José Luis Del Pozo: The Fight Against Gram-Positive Bacterial Infections丨ECCMID 2023

Dr. José Luis Del Pozo: The Fight Against Gram-Positive Bacterial Infections丨ECCMID 2023

In an era where antibiotic-resistant infections like MRSA are on the rise, healthcare professionals are constantly in search of potent drugs to combat these pathogens. The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) presented an opportunity to explore advancements in this area. One of the notable voices at this congress was Dr. José Luis Del Pozo from the University of Navarra. Infectious Disease Frontline had a chance to sit down with him for a comprehensive discussion.
Antimicrobial Susceptibility Testing: Insights from EUCAST Pioneer, Dr. Gunnar Kahlmeter丨ECCMID 2023

Antimicrobial Susceptibility Testing: Insights from EUCAST Pioneer, Dr. Gunnar Kahlmeter丨ECCMID 2023

Antimicrobial susceptibility testing (AST) is critical in modern medicine, helping doctors determine which antibiotics are most likely to be effective against particular bacterial infections. Across the globe, standards for AST primarily revolve around the European EUCAST and the American CLSI. Dr. Gunnar Kahlmeter, one of the main architects of EUCAST, offers unique insights into the past, present, and future of AST.
Dr. Anne J. Gonzales-Luna: Progress in Pediatric Clostridioides difficile Infection丨ECCMID 2023a

Dr. Anne J. Gonzales-Luna: Progress in Pediatric Clostridioides difficile Infection丨ECCMID 2023a

Clostridioides difficile, a primary cause of antibiotic-associated diarrhea, presents a spectrum of clinical manifestations. While less prevalent in children than adults, the incidence of pediatric Clostridioides difficile infection (CDI) is on the rise. The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) dedicated a session to shed light on this pressing issue, with Dr. Anne J. Gonzales-Luna from the University of Houston College of Pharmacy offering her expertise.
Youth Forum of APACC 2023  | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

Youth Forum of APACC 2023  | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

Hello everyone, I'm Xiaosheng Liu , a graduate student from Professor Taisheng Li's team of Peking Union Medical College Hospital, China. My primary research focus is on the mechanisms underlying immunological non-response in HIV/AIDS patients after long-term antiviral therapy and the development of therapeutic drugs for this condition. I'm delighted to participate in this year's APACC conference (2023) and present two poster studies conducted by our team at the conference. APACC is the most cutting-edge and top academic conference in the Asia-Pacific region for HIV/AIDS, and I hope to broaden my knowledge in various aspects through this conference.
Dr. Reena Rajasuriar: Eliminating Regional Disparities to Achieve the 2030 End of HIV Epidemic

Dr. Reena Rajasuriar: Eliminating Regional Disparities to Achieve the 2030 End of HIV Epidemic

Co-President of APACC 2023, Chief Researcher at the Center of Excellence for HIV/AIDS Research (CERiA) at the University of Malaya, Associate Professor at the Faculty of Medicine, University of Malaya, Research Fellow at the Peter Doherty Institute for Infection and Immunity, University of Melbourne. She is primarily responsible for the University of Malaya's HIV Immunology Translational Research Program, with her current research focus on the immunopathogenic mechanisms of aging in HIV/AIDS patients and their impact on patient health.
Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

Honorary Dr. at the Amsterdam University Medical Center, University of Amsterdam, former President of the European AIDS Clinical Society (EACS) (2008-2012), former Regional Director for Europe and Central Asia on the Governing Council of the International AIDS Society (IAS) (2006-2014), Co-Chair of the 22nd International AIDS Conference (AIDS 2018), Director of the Netherlands HIV Monitoring Foundation, member of the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NAID) HIV Vaccine Data and Safety Monitoring Board, and member of various committees including CROI, EACS, and HIV Glasgow.